This article was originally published in The Rose Sheet
U.S. market share of the Revlon and Almay brands combined declined 5.3% to 21.3% in the third quarter. Revlon share did not decline by 5.3% and Almay share did not drop by 21.3% as reported in the Nov. 22 issue of "The Rose Sheet" (1"The Rose Sheet" Nov. 22, 2004, p. 4)...
You may also be interested in...
Revlon will undertake a review of its existing ad campaign, indicating the company may be looking to reposition its marketing approach as it continues to struggle to jumpstart sales
A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.